HUTCHMED Transitions to New Leadership with Appointments of Non-executive Director and Special Advisor to Technical Committee

HUTCHMED (China) Limited—the company whose shares are traded on Nasdaq/AIM (HCM) and Hong Kong Exchange (13)—is pleased to announce that after July 13, 2023, it will take effect. With a history of success, the future looks even brighter for the Company and its investors.

Mr. Lefei Sun has stepped down from his role as Non-executive Director and member of the Technical Committee of HUTCHMED, following his departure from General Atlantic.

Ms Ling Yang, Managing Director of The Carlyle Group and Co-head of Carlyle Asia Healthcare, has been appointed as a Non-executive Director of HUTCHMED. She brings her wealth of knowledge and expertise to the board and is looking forward to her tenure until the next general meeting where she will put her name forward to be re-elected.

The Board of Directors of HUTCHMED is pleased to announce the appointment of Ms. Yang to their Board. With her extensive experience in biotechnology company management, business strategy, capital markets and mergers and acquisitions, Ms. Yang is set to bring a wealth of value to HUTCHMED.

Ms. Yang previously held the position of Managing Director at Carlyle Asia Healthcare, leading investment and portfolio activities in China. Carlyle owns about 4.7% of the ordinary shares of HUTCHMED through its affiliate CA Fern Parent, showing their confidence in this important new appointment.

The Board of HUTCHMED wishes to extend its utmost appreciation to Mr Lefei Sun for his invaluable contributions to the Company. We wish him the very best in his future endeavours. Additionally, we are most delighted to welcome Ms Ling Yang to the Company. Her wealth of expertise in the life sciences and healthcare investment spheres, we are convinced, will be indispensable in accelerating the achievement of our aspirations.

Ms Yang, a 43-year-old chairwoman and non-executive director of ADICON Holdings Limited, is a proud summa cum laude and Phi Beta Kappa member holding bachelor’s degrees in economics and computer science from the esteemed Smith College. She furthered her education by obtaining a Master of Business Administration from Harvard Business School.

Yang’s career history also includes time spent at KKR Asia Limited, Carlyle, and The Goldman Sachs Group, Inc, for which she held the positions of principal, associate, and analyst, respectively. Currently, Yang is a director of Shenzhen Salubris Pharmaceuticals Co., Ltd, and non-executive director of Ambio Pharmaceuticals and Ambio, Inc. Additionally, she is chairwoman of Adicon (Hangzhou) Clinical Laboratories Co., Ltd. and Aidiken (Hangzhou) Biotech Co., Ltd.; and director of Adicon International Limited and Manson Grand International Limited.

Her past work experience included that of a non-executive director of Ambio Holdings, Inc. Altogether, Ms Yang has accumulated a wealth of knowledge and prominent positions in the business world.

Ms Yang has been appointed as a Non-executive Director of the Company and will serve on the Board until the next general meeting. She will be re-elected annually, for successive 12-month periods, though either party may terminate her appointment earlier, in writing. As a Non-executive Director, Ms Yang offers her important contributions free of any fees.

Ms Yang was recently appointed as a director of HUTCHMED, and prior to this had no history of directorships or partnerships during the last five years. Moreover, apart from her engagement with Carlyle, she has no affiliations with any of the Directors, senior management or substantial or controlling shareholders of HUTCHMED. Furthermore, she does not hold any interest in the ordinary shares of HUTCHMED, as per the regulations of the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong).

We are delighted to announce the appointment of Ms Yang to HUTCHMED, in line with Rule 17 and Schedule 2(g) of the AIM Rules for Companies and Rule 13.51(2) of the HK Listing Rules. We are excited to be welcoming Ms Yang to the organization and we are certain that she will bring a wealth of knowledge and experience to her new role.

Mr Sun has peacefully stepped down from his position as a Director of the Company in accordance with Rule 13.51(2) of the HK Listing Rules. He has confirmed his agreement with the Board’s decision and there is nothing further that the Company’s shareholders needs to be made aware of.

Appointment of Special Advisor to the Technical Committee

After thoughtful consideration by the Board and following conversations with Professor Solange Peters, the Company proudly announced their decision to appoint Professor Peters as Special Advisor to the Technical Committee with effect from July 12, 2023. Professor Peters will not be joining the Board, however, her expertise will bring an added dimension to the Committee.

The Board is confident that, given Professor Peters’ expertise and reputation in the fields of biopharmaceutical research in oncology and immunology, appointing her as Special Advisor to the Technical Committee (instead of the position of an Independent Non-executive Director, as previously proposed) will make the most of Professor Peters’ contributions to the scientific research and strategy of HUTCHMED. With her highly-valued experience in these areas, the Board is sure that Professor Peters will play an invaluable role in taking the company to new heights.

The Board of HUTCHMED is delighted to announce the appointment of Professor Peters as Special Advisor to its Technical Committee, hailing her vast expertise in oncology and immunology as an invaluable asset in the development of treatments for diseases in the same fields. Simon To, Chairman of HUTCHMED, expresses his enthusiasm and readiness to collaborate with Professor Peters, stating: “We look forward to working with her.”


HUTCHMED, a groundbreaking commercial-stage biopharmaceutical firm, is forging ahead in its mission to discover and develop targeted treatments and immunotherapies for cancer and immunological diseases.

With a team of experienced oncology/​immunology professionals, the company has already secured approval for three of its oncology drugs in China. HUTCHMED employs over 5,000 personnel worldwide, providing patients everywhere with an opportunity to access these innovative drugs.

Leave a Comment